Joshua Lev Sells 6,667 Shares of electroCore (NASDAQ:ECOR) Stock

by · The Cerbat Gem

electroCore, Inc. (NASDAQ:ECOR – Get Free Report) CFO Joshua Lev sold 6,667 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $9.00, for a total transaction of $60,003.00. Following the completion of the sale, the chief financial officer directly owned 84,889 shares of the company’s stock, valued at approximately $764,001. The trade was a 7.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

electroCore Stock Performance

Shares of electroCore stock opened at $9.76 on Friday. The firm has a 50-day moving average of $6.60 and a 200-day moving average of $6.10. The stock has a market cap of $81.01 million, a PE ratio of -5.51 and a beta of 0.68. electroCore, Inc. has a 52-week low of $4.16 and a 52-week high of $10.27.

electroCore (NASDAQ:ECOR – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.59). The company had revenue of $9.58 million during the quarter, compared to analysts’ expectations of $9.01 million. electroCore had a negative net margin of 44.08% and a negative return on equity of 1,956.38%. Equities research analysts predict that electroCore, Inc. will post -1.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ECOR shares. Zacks Research raised shares of electroCore from a “strong sell” rating to a “hold” rating in a research report on Friday, March 27th. raised shares of electroCore to a “strong-buy” rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of electroCore in a research report on Friday, March 27th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, electroCore currently has an average rating of “Hold” and an average price target of $18.00.

View Our Latest Report on electroCore

Institutional Investors Weigh In On electroCore

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jaffetilchin Investment Partners LLC lifted its position in electroCore by 7.4% during the fourth quarter. Jaffetilchin Investment Partners LLC now owns 52,363 shares of the company’s stock worth $235,000 after purchasing an additional 3,600 shares during the period. Two Sigma Investments LP lifted its position in electroCore by 20.8% during the third quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock worth $122,000 after purchasing an additional 4,231 shares during the period. International Assets Investment Management LLC lifted its position in electroCore by 15.2% during the fourth quarter. International Assets Investment Management LLC now owns 88,720 shares of the company’s stock worth $398,000 after purchasing an additional 11,700 shares during the period. FNY Investment Advisers LLC bought a new stake in electroCore during the fourth quarter worth about $82,000. Finally, Jane Street Group LLC raised its stake in electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock worth $246,000 after acquiring an additional 19,599 shares in the last quarter. Institutional investors own 26.74% of the company’s stock.

About electroCore

(Get Free Report)

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.

Featured Stories